Daxor Announces Kaiser Permanente of Los Angeles, CA Purchases BVA-100 Blood Volume Analyzer

NEW YORK, NY--(Marketwire - May 6, 2008) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the purchase of a Blood Volume Analyzer BVA-100® by the Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.

Kaiser Permanente is the largest nonprofit health plan in the United States, serving 8.2 million members in 9 states and the District of Columbia, with 32 medical centers and over 13,700 physicians. Kaiser's first BVA-100 will be located at Kaiser's Los Angeles Medical Center.

Kaiser Permanente is an integrated health delivery system, which means that Kaiser Permanente provides and coordinates the entire scope of care for its members. As a nonprofit health plan, Kaiser Permanente is driven by the needs of its members rather than the needs of shareholders. Kaiser Permanente's Los Angeles Medical Center is a 439-bed tertiary medical center.

Daxor's Blood Volume Analyzer BVA-100 will be located within the Los Angeles Medical Center's Nuclear Medicine Department, and will be utilized by cardiology and various critical care units to diagnose blood volume derangements in various medical and critical care conditions.

Other leading medical institutions that have purchased the Blood Volume Analyzer BVA-100 include Mayo Clinic, Cleveland Clinic, NYU Medical Center, Methodist Hospital of San Antonio, and Queens Medical Center of Hawaii. Daxor Corporation manufactures and markets the BVA-100, the only FDA approved semi-automated Blood Volume Analyzer, which measures human blood volume. The BVA-100 is used in conjunction with Volumex™, Daxor's single use diagnostic kit.

For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh (COO) at 212-330-8515, stephen@daxor.com or Diane Meegan (Investor Relations) at 212-330-8512, dmeegan@daxor.com.

Contact Information: Contacts: Stephen Feldschuh COO 212-330-8515 Diane Meegan Investor Relations 212-330-8512